The phase III IMspire170 trial compared cobimetinib + atezolizumab to pembrolizumab in patients with BRAF wild-type melanoma and found no differences in PFS or ORR based on NRAS, NF1 or TWT molecular drivers in either of the two study arms [21]. Here, NRAS is linked to melanoma.